New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
07:20 EDTICPTIntercept data should be positive catalyst for shares, says Oppenheimer
Oppenheimer predicts that top-line data for Intercept's Phase 2 FLINT study in NASH, expected to be released in July, will be a positive catalyst for the stock. The firm thinks that the risk/reward ratio for the stock heading into the data release should be attractive as long as expectations remain modest. It keeps a $499 price target and Outperform rating on the stock.
News For ICPT From The Last 14 Days
Check below for free stories on ICPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2014
17:05 EDTICPTOrbiMed reports 7% stake in Intercept
Subscribe for More Information
August 26, 2014
07:46 EDTICPTIntercept Pharmaceuticals volatility at low end of historic range
Subscribe for More Information
August 18, 2014
10:57 EDTICPTOptions with decreasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use